MDT

Medtronic plc
CAPPED RATING

Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.

Medtronic plc (MDT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Revisions (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
D+
Factor Score 1.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 25.3
EV / EBITDA N/A
Rev Growth YoY 13.7%
Gross Margin 65.3%
Price Return 3M 14.5%
Price Return 12M 10.9%
Catalyst Signal +0.01
Market Cap $131.6B
TTM Revenue $37.5B
Price / Sales 3.5
ROE 10.6%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (3.0) C (2.3) B+ (3.6) B+ (3.6) D+ (1.6) C+ (2.8)
2026-11-09 B- (2.9) C (2.3) B+ (3.6) B (3.4) D+ (1.6) C+ (2.8)
2026-11-03 B- (3.0) C (2.2) B+ (3.6) B (3.2) D+ (1.6) C+ (2.7)
2026-11-02 B- (3.0) C (2.2) B+ (3.6) B- (3.1) D+ (1.7) C+ (2.7)
2026-10-26 B- (3.0) C (2.2) B+ (3.6) B- (3.0) B- (2.9) B- (3.0)
Page 1 of 10
…